Harrow Health, Inc. (NASDAQ:HROW – Get Free Report) major shareholder Opaleye Management Inc. purchased 29,400 shares of Harrow Health stock in a transaction dated Friday, April 19th. The shares were acquired at an average cost of $10.56 per share, for a total transaction of $310,464.00. Following the transaction, the insider now directly owns 3,775,000 shares […]
Harrow Health, Inc. (NASDAQ:HROW – Get Free Report) CEO Mark L. Baum acquired 9,000 shares of the firm’s stock in a transaction on Friday, March 22nd. The shares were bought at an average cost of $11.59 per share, for a total transaction of $104,310.00. Following the completion of the acquisition, the chief executive officer now […]
Harrow Health, Inc. (NASDAQ:HROW – Get Free Report) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 4,890,000 shares, a decline of 20.0% from the November 15th total of 6,110,000 shares. Based on an average daily trading volume, of 682,900 shares, the days-to-cover […]
Private Capital Management LLC decreased its holdings in Harrow Health, Inc. (NASDAQ:HROW – Free Report) by 1.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,152,346 shares of the company’s stock after selling 13,375 shares during the quarter. Harrow Health accounts for approximately […]
Prelude Capital Management LLC boosted its stake in Harrow Health, Inc. (NASDAQ:HROW – Free Report) by 6.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 46,456 shares of the company’s stock after purchasing an additional 2,753 shares during the quarter. Prelude Capital Management LLC […]